退行性胸主动脉瘤与夹层性胸主动脉瘤的改良衰弱指数及死亡率比较
单中心回顾性研究纳入2015至2024年287例胸主动脉瘤患者,退行性组124例(43.2%),夹层组163例(56.8%)。退行性组mFI-5和mFI-11均显著更高,1年、5年及主动脉相关死亡率均更高;接受TEVAR者术后1年和5年死亡率也更高,mFI是全队列术后死亡的最强预测因子。
要点
- 退行性胸主动脉瘤患者mFI-5和mFI-11显著高于夹层性胸主动脉瘤患者。
- 退行性组1年、5年及主动脉相关死亡率均显著高于夹层组。
- 接受TEVAR者退行性组术后1年和5年死亡率显著更高,mFI为术后死亡最强预测因子。
核心结论
- 退行性胸主动脉瘤患者mFI-5和mFI-11高于夹层性胸主动脉瘤患者,且与更高的1年死亡率、5年死亡率、主动脉相关死亡率及TEVAR术后死亡率相关。
研究设计与样本
- 单中心三级血管中心回顾性研究,纳入2015年1月至2024年12月诊断的退行性(124/287,43.2%)或夹层性(163/287,56.8%)胸主动脉瘤患者。
- 衰弱采用5因子(mFI-5)和11因子(mFI-11)改良衰弱指数评估。
- 死亡率分析采用Kaplan-Meier曲线,关联采用多变量Cox回归分析。
主要发现
- 退行性组1年死亡率18.0%、5年死亡率55.6%、主动脉相关死亡率10.5%;夹层组分别为5.6%(P < 0.001)、16.0%(P < 0.001)、1.8%(P = 0.002)。
- 接受TEVAR者,退行性组术后30天、1年、5年死亡率分别为4.8%、30.0%、50.0%;夹层组分别为2.1%(P = 0.492)、4.8%(P < 0.001)、10.0%(P = 0.009)。
- 退行性组mFI-5均值1.61 vs. 1.22(P < 0.001),mFI-11均值2.12 vs. 1.36(P < 0.001),均显著更高。
- mFI是全队列术后死亡的最显著预测因子:mFI-5 HR 2.71(P < 0.001),mFI-11 HR 2.27(P < 0.001)。
临床怎么用
- 对胸主动脉瘤患者应评估mFI-5和mFI-11,识别衰弱高风险人群。
- 退行性胸主动脉瘤患者即使接受TEVAR,术后远期死亡风险仍较高,需加强围术期及术后随访管理。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The prevalence of thoracic aortic aneurysm (TAA) is increasing with aging population and prevalence of imaging as incidental discovery. More patients require operation for TAA and frailty predicts negative surgical outcomes better than chronological age alone in vascular patients. The aim of this study was to compare patients with degenerative and chronic dissecting aneurysm, with respect of their association with modified frailty index (mFI) and mortality with or without thoracic endovascular aortic repair (TEVAR). METHODS: Patients diagnosed with degenerative or dissecting TAA in a tertiary referral vascular center from January 2015 to December 2024 were included. Frailty was measured with 5-factor (mFI-5) and 11-factor (mFI-11). Demographics and characteristics of TAA were analyzed by chi-squared test and univariate analysis. Mortality was analyzed with Kaplan-Meier curve, while association were examined by multivariate Cox regression. RESULTS: Degenerative TAA constituted 124/287 (43.2%) patients and dissection accounted for 163/287 (56.8%) patients. For patients with degenerative aneurysms, 1-year mortality, 5-year mortality, and aortic-related mortality (ARM) were 18.0%, 55.6%, and 10.5%, respectively. For dissecting aneurysms, 1-year, 5-year, and ARM were 5.6% (P < 0.001), 16.0% (P < 0.001), and 1.8% (P = 0.002), respectively. For patients who underwent TEVAR, the 30-day, 1-year and 5-year postoperative mortality for patients with degenerative TAA were 4.8%, 30.0%, and 50.0%. The respective postoperative mortality for dissecting TAA were 2.1% (P = 0.492), 4.8% (P < 0.001), and 10.0% (P = 0.009). mFI-5 (mean 1.61 vs. 1.22, P < 0.001) and mFI-11 (mean 2.12 vs. 1.36, P < 0.001) were significantly higher in degenerative TAA patients. mFI also were the most significant factor to predict postoperative mortality of the entire cohort (hazard ratio [HR]: 2.71, P < 0.001 for mFI-5; HR: 2.27, P < 0.001 for mFI-11). CONCLUSION: Patients with degenerative TAA had higher mFI-5 and mFI-11 when compared to patients with dissecting TAA. Degenerative TAA is also associated with higher 1-year mortality, 5-year mortality, ARM, and postoperative mortality in patients who underwent TEVAR.
引用
- Chan BYL, Chan YC, Groenewald C, et al. Degenerative Thoracic Aortic Aneurysm is Associated With Higher Modified Frailty Index and Mortality Compared to Patients With Dissecting Thoracic Aortic Aneurysm, With or Without Thoracic Endovascular Aortic Repair. Ann Vasc Surg. 2026. PMID: 41951205. doi:10.1016/j.avsg.2026.03.054
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。